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ABSTRACT
Hodgkin lymphoma (HL) resistant to conventional therapies is increasing, making of interest the search for
new schemes of treatment. Members of the “A Disintegrin And Metalloproteases” (ADAMs) family, mainly
ADAM10 or ADAM17, have been proposed as therapeutic targets in solid tumors and some ADAMs
inhibitors have been shown to exert antitumor effects. We have previously described an overexpression of
ADAM10 in HL, together with increased release of NKG2D ligands (NKG2D-L) and reduced activation of
effector T lymphocytes with anti-lymphoma capacity. Aim of the present work was to verify whether
inhibition of ADAM10 in HL cells could restore the triggering of NKG2D-dependent anti-lymphoma T cell
response. As no selective ADAM10 blockers have been reported so far, we synthesized the two
hydroxamate compounds LT4 and MN8 with selectivity for ADAM10 over metalloproteases (MMPs), LT4
showing higher specificity for ADAM10 over ADAM17. We show that (i) HL lymph nodes (LN) and cultured
HL cells express high levels of the mature active membrane form of ADAM10; (ii) ADAM10 is the major
sheddase for the NKG2D-L in HL cells; (iii) the new LT4 and MN8 compounds strongly reduce the shedding
of NKG2D-L by HL cell lines and enhance the binding of NKG2D receptor; (iv) of note, these new ADAM10
inhibitors increase the sensitivity of HL cell lines to NKG2D-dependent cell killing exerted by natural killer
and gd T cells. Overall, the biologic activity of LT4 and MN8 appears to be more potent than that of the
commercial inhibitor GI254023X.
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MIC-A; MIC-B; TGFbeta;
ULBPs
Introduction
The ADAMs family is composed of multidomain proteins,
including ADAM10, involved in the so-called ectodomain
shedding, a proteolytic process essential for cell development,
migration and wound healing.1,2 The active form of these
enzymes is primarily located at the cell surface and is triggered
by activation of protein kinase C, inhibition of phosphatases or
increase in the intracellular calcium levels.1-3 Among the best-
known ADAM substrates, there are precursor forms of growth
factors or cytokines, some of which, such as tumor necrosis fac-
tor (TNF)-a or epithelial growth factor (EGF), are involved in
the pathogenesis and development of cancer.4-6 As an example,
ADAM10 and ADAM17 have been reported to promote epi-
thelial tumor growth by releasing epidermal growth factor
(HER)/EGF receptor ligands.3,4 The evidence for ADAMs
involvement in cancer is also supported by the finding that
overexpression of these enzymes relates to parameters of tumor
progression (tumor size, grade, metastasis and LN involve-
ment).2,3,5 ADAM10 and ADAM17 may also function as shed-
dases for the so-called “stress molecules,” including the MHC-
class-I-related MIC-A and MIC-B, and the UL16-binding pro-
teins (ULBPs).7,8 These molecules are expressed at the cell sur-
face during tumor transformation and can be upregulated by
all-trans-retinoic acid (ATRA) or sodium valproate (VPA).9-14
Once the natural killer group2 (NKG2D) is engaged by these
antigens (called NKG2D ligands, NKG2D-L), NK and gdT
lymphocytes initiate a rapid immune response against tumor
cells preceding the expansion of specific abT cells.9-12 In partic-
ular, we described that this mechanism is active in chronic lym-
phocytic leukemia, acute myeloid leukemia, non-Hodgkin and
HL.13-16 In these cancers, NK and gdT cells proliferate in
response to NKG2D-L bearing tumors and exert cytolytic activ-
ity against autologous cancer cells.13-16 However, when
NKG2D-L are shed by tumor cells, they interact with the
NKG2D receptor on effector lymphocytes and hinder the rec-
ognition of neoplastic cells.8,11,12,14-16 Soluble (s)NKG2D-L can
also downregulate NKG2D expression on effector lymphocytes,
contributing to tumor escape;9 moreover, serum levels of
sNKG2D-L have been shown to have prognostic significance in
acute and chronic leukemias, multiple myeloma and lympho-
mas.14-19 Along this line, we reported overexpression of
ADAM10 in the LN microenvironment in HL, together with
impaired T lymphocyte stimulation of antitumor activity and
increased levels of sNKG2D-L.16
Based on these data, ADAMs have been proposed as both
biomarkers and therapeutic targets for cancer.1-6 Some
ADAM10 or ADAM17 inhibitors with antitumor effects have
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been described;20-23 however, to our knowledge, no selective
ADAM10 blockers and no data in HL have been reported so far.
Thus, we developed inhibitors with progressively higher specific-
ity for ADAM10 to enhance efficiency and selectivity of action.
In this paper, we show that (i) the mature active membrane
form of ADAM10 is expressed in HL LN and on HL cells; (ii)
ADAM10 is the major sheddase for the NKG2D-L in HL cells;
(iii) the new hydroxamate compounds LT4 and MN8 reduce
the shedding of NKG2D-L by HL cell lines and enhance the
binding of NKG2D receptor; (iv) exposure to these new specific
ADAM10 inhibitors increases the sensitivity of HL cell lines to
NKG2D-dependent cell killing.
Results
The mature active membrane form of ADAM10 is
expressed in HL LN and on HL cells and is relevant for
NKG2D-L shedding
Cell suspensions from LN bioptic specimens were obtained
from 10 HL (5 depicted in Fig. 1A) patients and subjected to
Western blot analysis for ADAM10: in all samples, the mature
form of ADAM10 was mainly detected (Fig. 1A). The HL cell
lines KMH2, L428, from pleural effusion, and L540, from bone
marrow of HL patients, representative of the nodular sclerosis
(L428, L540) and mixed cellularity (KMH2) HL histotypes, and
the RS773 cell lines that we previously described16(mixed cellu-
larity, obtained from LN5 of Fig. 1A) did express the mature
ADAM10 form that is almost the only form detectable in L428
and RS773 cells (Fig. 1B). All the HL cells analyzed showed
surface expression of mature ADAM10 evidenced by
immunofluorescence with the specific mAb and FACS analysis
(Fig. 1Ca for KMH2, Cb for L540 and Cc for L428; Fig. 1Eb for
RS773,16). This was also true for mesenchymal stromal cells
(MSC) isolated from LN cell suspension (Fig. 1D and 1Ea for
surface expression,16). Thus, the mature membrane form of
ADAM 10, that is described to display the enzymatic activity,1-
3 is prevalent in lymphoma cells, in keeping with our previous
report of ADAM10 expression in situ in HL.16 In the same
report, we described a significant shedding of different
NKG2D-L targets for ADAM10, including MIC-A and ULBPs,
expressed by lymphoma cells.16 The expression of MIC-A,
MIC-B, ULBP2 and ULBP3 (with the exception of ULBP3 on
L428) was low in all the HL cell lines tested (Fig. S1A); in par-
ticular, deglycosylation experiments showed that HL cell lines
express mainly the non-truncated form of MIC-A (Fig. S1C).
Likewise, the LN cell suspensions mostly displayed a dull
expression of the NKG2D-L (Fig. S1B). Of note, soluble ULBP3
was found in the supernatant (SN) of LN cell suspensions
(Fig. S1D).
Since these ligands represent a substrate also for
ADAM17,7,8,24 we asked which sheddase was active in HL
tumor cells. To address this question, either ADAM10 or
ADAM17 were silenced in KMH2 (Fig. 2A, B) or L428
(Fig. 2C, D). Silencing led to a significant reduction of
ADAM10 mature form (panels Aa, Ca) (densitometric ratio:
0.59 for KMH2 and 0.1 for L428 vs siNT set to 1), and its
expression at the cell surface (panels Ab, MFI: 20 vs. 100 a.u.
and Cb, MFI: 100 vs. 800 a.u.). Likewise, ADAM17 silencing
consistently reduced the protein (Fig. 2Aa, 2Ca: densitometric
ratio: 0.79 for KMH2 and 0.2 for L428). Of note, ADAM10
silencing resulted into decreased shedding of the NKG2D-L
Figure 1. The mature membrane form of ADAM10 is expressed on HL cells. Panels (A), (B), (D) Lysates obtained from HL LN cell suspensions (A) or HL cell lines (B) or LN
MSCs obtained by culturing LN cell suspensions from HL patients (D) were subjected to Western blot as described in Materials and Methods; membranes were probed
with the anti-ADAM10 or anti-b actin mAb followed by the relevant HRP-conjugated secondary antibodies and developed with the HRP substrate. In each blot, the pre-
cursor form (p) and the mature form (m) of ADAM10 molecule is indicated. Panels (C) and (E) Surface expression of ADAM10 on KMH2, L540, L428 (Ca, Cb, Cc, dark gray
histograms) or MSC773 or RS773 (Ea, Eb) was evaluated with the specific mAb directed against the mature form of ADAM10 followed by APC-conjugated GAM and FACS
analysis; results are expressed as Log far red fluorescence intensity, a.u., vs. number of cells.
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MIC-B (Fig. 2Ba, Da) or ULBP3 (Fig. 2Bb, Db); although to a
lesser extent, also MIC-A shedding was reduced (from 6 to
4 ng/106 cells in KMH2 cells and from 5 to 3 ng/106 in L428
cells, not shown). In turn, silencing of ADAM17 rather inhib-
ited the release of sALCAM (Fig. 2Bc and 2Dc), that is reported
as preferential substrate for ADAM17.25,26
ADAM10 specific inhibitors reduce the shedding of NKG2D-
L by HL cells and enhance the binding of NKG2D receptor
To counteract the enzymatic effect of ADAM10 in HL cells, the
two hydroxamate compounds LT4 and MN8 were synthesized
and tested in an in vitro enzymatic inhibition assay (Materials
and Methods) to check the inhibitory effect of the two com-
pounds on either ADAM10 or ADAM17. First, both inhibitors
displayed high selectivity over MMPs, namely MMP-1 MMP-2,
MMP-9 and MMP14, at variance with the commercial
GI254023X (GIX, Table 1). Moreover, LT4 showed high selec-
tivity for ADAM10 over ADAM 17 (IC50 40 nM vs. 1500 nM
on ADAM17, Table 1). These inhibitors were compared to GIX
and the reported compound 21 (JG26),25 the latter showing a
higher selectivity for ADAM17 over ADAM10 (IC501.9nM vs.
150nM, Table 1). Soluble (s)MIC-A, sMIC-B, sULBP2, sULBP3
(as substrates for ADAM10 or ADAM17 sheddases) and sAL-
CAM (as a preferential substrate for ADAM17) were measured
by ELISA in the SN collected from HL cell lines untreated or
exposed for 24 h to the ADAM10 inhibitors GIX, JG26, LT4,
MN8, (from 10 mM to 1 mM) or to the solvent alone (DMSO).
To maximize ADAMs activity, in some samples 100 mM
sodium orthovanadate (Na3VO4) was added as pervanadate for
40 min before collecting SN. LT4 and MN8 could inhibit both
constitutive (Fig. 3A) and pervanadate-induced (Fig. 3B) shed-
ding of sMIC-A (Fig. 3Aa, Ba), sMIC-B (Fig. 3Ab, Bb), sULBP2
(Fig. 3Ac, Bc) and sULBP3 (Fig. 3Ad, Bd) by L428 cells with
higher efficiency (inhibition detectable up to 5–2.5 mM) than
JG26 or GIX (active at 5–10 mM concentration). In turn, JG26,
GIX and MN8 were more efficient in reducing pervanadate
induced release of sALCAM (Fig. 3C). Thus, the ADAM10
inhibitor LT4 is the most efficient in preventing the shedding
of NKG2D-L, with low activity on ALCAM release. Of note,
LT4 pre-treatment of L428 cells could prevent the reduction of
Figure 2. ADAM10 silencing leads to decreased shedding of NKG2D-L. KMH2 and L428 cells were transfected with ADAM10 (siADAM10) or ADAM17 (siADAM17) siRNA or
non-targeting siRNA (siNT) pool as negative control (KMH2: panels A, B; L428: panels C, D). Protein expression was analyzed by Western blot (panels Aa and Ca), and
FACS analysis (Ab and Cb; in each histogram the percentage and MFI of positive cells is shown) with the specific anti-ADAM10 or anti-ADAM17 antibodies, 72 h after
transfection. Soluble MIC-B (Ba, Da) or ULBP3 (Bb, Db) or sALCAM (Bc, Dc) were evaluated by ELISA in SN (collected upon further 24 h of culture 72 h after transfection).
Results in (B) and (D) are expressed as pg/mL/105 cells and are the mean § SD from three independent experiments. p<0.001 vs siNT.
Table 1. In vitro enzymatic activity (IC50nM values)
a of new compounds LT4 and
MN8 and the reference compounds JG26 and GI254023X.
Compound ADAM10 ADAM17 MMP1 MMP2 MMP9 MMP14
LT4 40 1,500 346,000 5,400 24,000 100,000
MN8 9.2 90 >200,000 370 4,500 50,000
JG26 150 1.9 >500,000 240 1,630 19,500
GI254023Xb 27 860 125 2.1 5.1 88
aThe IC50 values are the average of three determinations with a standard deviation
of <10%.
bData from our laboratory (see also Materials and Methods).
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ULBP2 surface expression that follows pervanadate exposure
(from 71% to 59% of positive cells in the presence of LT4, from
71% to 32% without LT4, Fig. 3D); moreover, LT4-treated
L428 cells could efficiently bind the FcNKG2D chimeric recep-
tor also after exposure to pervanadate (Fig. 3E), suggesting that
LT4 counteracted the sheddase activity of ADAM10, triggered
by pervanadate, leading to stabilization of NKG2D-L expres-
sion and NKG2D receptor binding. Similar results were
obtained with L540 (Fig. S1A and Ca) and KMH2 (Fig. S1B
and Cb) cell lines: indeed, LT4 was the most efficient inhibitor
of NKG2D-L shedding (Fig. S2Aa and Ba for sMIC-A, Ab and
Bb for sMIC-B, Bc for sULBP2, Ac and Bd for ULBP3; note
that L540 is ULBP2 negative, Fig. S1) enhancing the binding of
FcNKG2D chimeric receptor as well (Fig. S2Ca for L540 and
Cb for KMH2), compared to GIX, JG26 and MN8. We also
tested the efficiency of LT4 on RS773 cells, derived in our labo-
ratory from an LN of an HL patient and previously described.16
As shown in Fig. S3, LT4 could inhibit (at 10 to 5 mM concen-
tration) both constitutive (panels Aa, Ac) and pervanadate-
induced (panels Ab, Ad) shedding of MIC-A (Aa, Ab) and
MIC-B (Ac, Ad) by RS773 cells. Moreover, LT4 was able to
increase the surface expression of MIC-A and MIC-B (Fig. S3B,
second vs. first row) and prevent the reduction of surface MIC-
A and MIC-B conceivably due to the activation of ADAM10 by
Figure 3. ADAM10 inhibitors reduce the shedding of NKG2D-L by HL cell lines and maintain the binding of NKG2D receptor. L428 cells were exposed to culture medium
alone, DMSO or GI254023X (GIX), JG26, MN8 or LT4 (at 10 to 2.5 mM concentration) for 24 h (panel A), followed by 100 mM Na3VO4 as pervanadate for 40 min at 37C
(panel B and C). Then, SN were harvested and sMIC-A (Aa, Ba), sMIC-B (Ab, Bb), sULBP2 (Ac, Bc), sULBP3 (Ad, Bd) or sALCAM (C) measured by specific ELISA. Results are
expressed as ng/mL/106 cells and are representative of four independent experiments. p <0.001 vs. DMSO. Panels (D) and (E) L428 cells exposed for 24 h to DMSO or
10 mM LT4 or 100 mM Na3VO4 as pervanadate, in the absence or presence of 10 mM LT4 as indicated, were harvested and evaluated for the expression of ULBP2 (D) with
the specific mAb followed by APC-conjugated GAM or for the binding of the chimeric receptor (FcNKG2D, panel E) followed by APC-conjugated anti-human Fc antiserum,
by FACS analysis; results are expressed as Log far red fluorescence intensity (arbitrary units, a.u.) vs. number of cells. In each subpanel: percentage and mean fluorescence
intensity (MFI, a.u.) of positive cells. One representative experiment out of four.
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pervanadate (Fig. S3B, fourth vs. third row). Accordingly, LT4
enhanced the binding of FcNKG2D chimeric receptor to RS773
cells (Fig. S3C, second vs. first histogram) and counteracted the
effect of pervanadate (Fig. S3C, fourth vs. third histogram).
MSC773 isolated from the same LN released detectable, but
lower, amounts of sMIC-A and MIC-B (Fig. S3Da and Db); of
note, LT4 was also able to inhibit pervanadate-induced increase
of sMIC-A and MIC-B shedding by MSC (Fig. S3Da and Db).
Exposure to ADAM10 inhibitors increases the sensitivity
of HL cell lines to NKG2D-dependent cell killing
The above-reported data suggest that inhibition of ADAM10
leads to a decreased shedding of NKG2D-L with stabilization
of their membrane expression and maintenance of NKG2D
receptor binding to HL cells. Thus, we asked whether the vari-
ous ADAM10 inhibitors improved the recognition of HL cell
lines by effector lymphocytes and the NKG2D-mediated killing.
To this aim, cytolytic activity of NK (Fig. 4A, and B) and gd T
cells (Fig. 4C) was analyzed against L428, L540 or KMH2 cell
lines at an E:T ratio of 10:1, before or after treatment for 24 h
of the HL cell lines with the ADAM10 inhibitors LT4 or MN8
(Fig. 4Aa, Ba, Ca) compared to GIX and JG26 (Fig. 4Ab, Bb) at
10 mM concentration.
We found that exposure of HL cells to the new inhibitors
LT4 and MN8 raised by 3-fold to 10-fold the NK cell kill-
ing of L428 (Fig. 4Aa), L540 (Fig. 4Ba) and KMH2
(Fig. S4). On the other hand, the increase of NK cell killing
of L428 and L540 treated with GIX or JG26 was 2–3-fold
(Fig. 4Ab, Bb). Of note, LT4 and MN8 could also enhance
Figure 4. Exposure to ADAM10 inhibitors increases the sensitivity of HL cell lines to NKG2D-dependent cell killing. Cytolytic activity of NK cells (n D 6, panel A and B) or
gd T cells (n D 6, panel C) was analyzed against L428 (Aa, Ab, Ca) or L540 (Ba, Bb, Cb) cell lines at E:T ratio of 10:1 in a 4-h 51Cr-release assay. Some samples were set up
after exposure of the target cell lines to either medium, or DMSO or LT4 or MN8 (Aa, Ba, Ca, Cb), GIX or JG26 (Ab, Bb) at 10 mM concentration for 24 h. In some samples,
effector cells were exposed to saturating amounts (5 mg/mL) of the anti-NKG2D mAb at the onset of the cytotoxicity assay; an unrelated mAb, matched for the isotype,
used as control, did not exert any effect (not shown). Results are expressed as % specific lysis calculated as described in Materials and Methods.
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the cytotoxicity exerted by gd T to L428 (Fig. 4Ca) and
L540 (Fig. 4Ca). Moreover, addition of the anti-NKG2D
mAb at the onset of the cytotoxicity assay led to a reduc-
tion of the cytolytic activity of NK (Fig. 4A and B and
Fig. S4) and gd T cells (Fig. 4C), both in the absence and
in the presence of the inhibitors, suggesting that the cyto-
toxicity in this system is mainly NKG2D-mediated; an
unrelated mAb, matched for the isotype, did not exert any
effect (not shown for L428 or L540 and Fig. S4 A and B for
KMH2). Thus, the new ADAM10 inhibitors LT4 and MN8
were more efficient than GIX and JG26 in sensitizing lym-
phoma cells to cytotoxic activity exerted by effector cells via
NKG2D/NKG2D-L interaction. We previously reported that
NKG2D-mediated killing of HL cells is impaired by TGFb
that downregulates the expression of the receptor at the
surface of effector cells, and this effect can be prevented by
neutralizing the cytokine.16 Along this line, we asked
whether the parallel treatment of cytotoxic effectors with an
anti-TGFb mAb and exposure of HL cells to ADAM10
inhibitors could achieve additional improvement of lym-
phoma cytolysis. As expected, TGFb downregulated the
expression of NKG2D at the surface of NK (Fig. 5Aa) or gd
T cells (Fig. 5Ab) and decreased the cytolytic activity of NK
cells against L428 HL cell line (Fig. 5Ba for NK and
Fig. 5Bb for gd T cells); both effects were neutralized by an
anti-TGFb mAb (Fig. 5A, and B). Of note, when assayed
against L428 cells exposed to LT4, the cytotoxicity exerted
by NK cells treated with TGFb and neutralized with the
anti-TGFb mAb was potentiated, showing an additional sig-
nificant improvement of cell lysis (Fig. 5B).
Discussion
There is increasing evidence that sheddases of the ADAM fam-
ily, in particular ADAM10 and 17 may become targets for anti-
cancer therapies.1-3,29 In particular, based on the literature and
our previous data,8,11,16 we hypothesized that modulation of
NKG2D-L expression and/or release, by inhibiting the ADAM-
sheddase enzymatic activity, could potentiate an anti-lymphoma
stress-related immune response. Some ADAM10 or ADAM17
inhibitors have been shown to have antitumor effects;20-23 how-
ever, no selective ADAM10 blockers have been reported and
data in HL are not available so far. To this aim, we focused on
the synthesis and use of specific inhibitors of either ADAM10 or
ADAM17. In this paper, we show that (i) the mature active
membrane form of ADAM10 is expressed in HL LN and at the
surface of HL cells; (ii) ADAM10 is the major sheddase for
NKG2D-L in HL cells; (iii) the new hydroxamate compounds
LT4 andMN8 reduce the shedding of NKG2D-L by HL cell lines
and enhance the binding of NKG2D receptor; (iv) exposure to
these new specific ADAM10 inhibitors increases the sensitivity
of HL cell lines to NKG2D-dependent cell killing.
In LN cell suspensions derived from HL patients, as well
as in cultured HL cells, we found that the mature form of
Figure 5. Improvement of HL cell lysis by exposure to ADAM10 inhibitor LT4 and anti-TGFb. Panel (A) NKG2D expression before (upper histograms) or after treatment
with TGFb (10 ng/mL), (middle histograms) or with TGFb and anti-TGFb mAb (1 mg/mL), on NK cells (Aa) or gd T cells (Ab). In each subpanel: percentage of positive cells
and MFI (a.u.). Panel (B) Cytolytic activity of NK cells (Ba) orgd T cells (Bb) was analyzed against L428 cell line at E:T ratio of 5:1 in a 4-h 51Cr-release assay. Some samples
were set up after exposure of the target cell lines to LT4 or MN8 at 10 mM concentration for 24 h. To some samples, we added effector cells exposed to TGFb (10 ng/mL),
with or without saturating amounts (1 mg/mL) of the anti-TGFb mAb, as indicated. Results are expressed as % inhibition or stimulation of specific lysis calculated as
described in Materials and Methods. p <0.001 vs. TGFb. p <0.001 vs. TGFb C anti-TGFb. #p <0.001 vs. TGFb C anti-TGFb on untreated L428 cells.
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ADAM10 is highly expressed and localized at the cell mem-
brane, supporting that the lymphoma microenvironment is
enriched in the active form of ADAM10. These data are in
keeping with our previous report on the overexpression of
this enzyme at the tumor site in HL.16 As reported, both
ADAM10 and ADAM17 may function as sheddases for the
so-called “stress molecules,” including MIC-A, MIC-B, and
ULBPs.7,8,28 Silencing of either ADAM10 or ADAM17 in
HL tumor cells led to discrete results: indeed, while
ADAM10 knock down resulted in reduced MIC-B and
ULBP3 shedding, ADAM17 silencing downregulated
ALCAM release. This suggests that ADAM10 is the main
sheddase for NKG2D-L in HL; thus, two inhibitors with
high (MN8 IC50 9.2 nM, LT4, IC50 40nM, Table 1) and
selective (LT4 IC50 40 nM vs. 1500 nM on ADAM17,
Table 1) activity on ADAM10 were developed to counteract
the enzymatic effect of ADAM10 in HL cells. LT4 and
MN8 could inhibit both constitutive and pervanadate-
induced shedding of all the NKG2D-L tested, by the HL
cell lines L428, L540, KMH2 and RS773, with higher effi-
ciency than JG26 or the commercial GI254023X (GIX). In
turn, JG26, GIX and MN8 were more efficient in reducing
the release of sALCAM induced by ADAMs pervanadate
stimulation. It has to be noted that the IC50 of GIX checked
by our group is different to that previously described,29
conceivably due to the more sensitive assay employed by us
(fluorimetric assay, described in Materials and Methods, vs.
scintillation proximity assay).29
Overall, the selective ADAM10 inhibitor LT4 is the most effi-
cient in preventing the shedding of NKG2D-L. Of interest, LT4
proved also to prevent the reduction of ULBP2 surface expres-
sion that follows pervanadate exposure in at least two HL cell
lines, with the result of a preserved ability to bind the FcNKG2D
chimeric receptor. This indicates that selective blocking of
ADAM10 sheddase by LT4 leads to the stabilization of
NKG2DL-NKG2D receptor interaction. Thus, we asked
whether HL cell lines exposed to the various ADAM10 inhibi-
tors become sensitive to NKG2D-mediated killing. Indeed, we
found that LT4 and MN8 exposure increased NKG2D-depen-
dent cell killing of HL cells with higher efficiency than less spe-
cific inhibitors such as GI254023X or JG26. Of note, LT4 and
MN8 could sensitize lymphoma cells to the cytotoxicity exerted
by NK and gd T cells. This effect could also be improved by
upregulation of NKG2D-L on target cells by ATRA or VPA;13-15
neither drugs influenced NKG2D-L shedding, in acute myeloid
leukemias or non-HLs or HL,14-16 nevertheless, VPA pre-treated
HL cells, besides upregulating NKG2D-L, appear to retain their
expression with high efficiency than untreated cells when
exposed to LT4 inhibitor. In addition to NKG2D/NKG2D-L,
other receptor ligand interactions are involved in tumor cells
killing by NK or T effector cells. In case of gd T cells, they usually
also kill different tumor cells via TCR-dependent recognition of
tumor-derived pyrophosphates.12,30,31 This can be exploited as
an additional therapeutic tool as amino-bis-phosphonates, com-
monly administered as anti-osteopenic agents in multiple mye-
loma are known to activate gd T cells and decrease regulatory
signals that may occur in the microenvironment.32,33
In conclusion, targeting selectively ADAM10 seems to stabi-
lize the interaction between NKG2D receptor and their ligands
expressed by HL cells and is sufficient to sensitize lymphoma
cells to the NKG2D-mediated cytotoxicity exerted by effector
lymphocytes. Possible major drawbacks of this therapeutic
approach might be the accessibility of ADAM10C cells at the
tumor site, that we show to be abundant according to immuno-
histochemistry,16 and the inhibition of cleavage of other
ADAM10 substrates. Nevertheless, it is conceivable that effec-
tor lymphocytes resident in the LN can be activated and exert
antitumor activity; furthermore, inhibition of cleavage of other
ADAM10 substrates, such CD30, a target for antibody-based
anti-lymphoma therapy,34 or TNFa, a reported growth factor
for lymphomas,35 might also be useful in HL.
Thus, ADAM10 inibitors may be proposed to become part
of anti-lymphoma therapeutic schemes and contribute to the
enhancement of antitumor immune response.
Materials and methods
Cells and LN specimens. The HL cell lines KMH2, L428,
obtained from pleural effusion, and L540, from bone marrow
of HL patients, were purchased from DSMZ GmbH
(Braunschweig, Germany). These cell lines are MIC-A/BC,
ULBP2/3Cand ALCAMC, except L540 that is ULBP2 negative
and ALCAM low (Fig. S2), and do not express ULBP1 and 4
(not shown). The RS773 cell line was obtained from a HL LN
and is MICA/B low and ULBP2/3 negative, as described.16 LN
MSCs were obtained by culturing LN cell suspensions from
HL patients in six-well plates (5 £ 106 cells/well) in MEM-a
(GIBCO) complete medium: their phenotype and characteri-
zation has been reported.16 After 3 d, non-adherent cells were
washed away and adherent cells cultured for additional 7 d.
LN biopsies of 10 HL patients, were obtained from the Unit
of Pathology, IRCCS-AOU San Martino-IST, Genoa, under
conventional diagnostic procedures, provided informed con-
sent and the study was approved by the institutional ethical
committee (IRB approval 0026910/07, renewal 03/2009). Sam-
ples taken as sentinel LN during surgical approaches and
resulted free of neoplastic disease, showed little expression of
ADAM10, not exceeding that of the housekeeping genes
tested.16 NK cell populations were separated from heparinized
blood of healthy donors with the specific Rosettesep isolation
kit (Stem Cell Technologies, Vancouver, Canada) according to
manufacturer’s instructions. gdT cells were purified with the
specific Minimacs separation kit (MiltenyiBiotec, Bergisch-
Gladbach, Germany) according to manufacturer’s instruction.
After this separation, NK or gd T cells, always >96 percent of
purity, were stimulated with 0.5 mg/mL of PHA in the pres-
ence of 10 ng/mL of recombinant interleukin-2 (rIL-2, Pepro-
TechEC, London, UK) in 96 U-bottomed microwells; after 15
d of culture, NK or gdT cells were always 99–100 percent.
Culture complete medium was composed of RPMI1640 (Bio-
chrom, Berlin, Germany) with 10% fetal calf serum (FCS, Bio-
chrom) supplemented with penicillin, streptomycin and L-
glutamine (Biochrom) and rIL-2.
Inhibitors. GI254023X (GIX) was purchased from Sigma
Chemicals Co. (St. Louis, MO). JG26 was synthesized as previ-
ously described,25,26 and MN8 and LT4, showing a IC50 pro-
gressively more selective for ADAM10, were newly synthesized
(Table 1). The various ADAM10 inhibitors (GIX, JG26, LT4 or
ONCOIMMUNOLOGY e1123367-7
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MN8) used on the differentHL cell lines, or on isolatedMSC, at 2.5
up to 10 mM concentration for 48, 72 and 96 h (and the solvent
DMSO at the same dilutions and time points) did not exert any
toxic effect, as assessed by evaluating the mitochondrial potential
upon staining with the dual emission fluorescent probe JC-1
(Molecular Probes, Life Technologies Italia, Monza) (not shown).
MMPs and ADAMs inhibition assays. Recombinant human
MMP-14 catalytic domain was a kind gift of Prof. Gillian
Murphy (Department of Oncology, University of Cambridge,
UK). Pro-MMP-1, pro-MMP-2, pro-MMP-9, and recombinant
human ADAM-17 (PF133) were purchased from Calbiochem
(Calbiochem Italia, Milan). Recombinant human ADAM10 was
from R&D Systems (Minneapolis, MN). Pro-enzymes were acti-
vated immediately prior to use with p-aminophenylmercuric ace-
tate (APMA 2 mM for 1 h at 37C for MMP-2, APMA 2 mM
for 2 h at 37C for MMP-1 and 1 mM for 1 h at 37C for
MMP-9). For assay measurements, the inhibitor stock solutions
(DMSO, 10 mM) were further diluted in the fluorometric assay
buffer (FAB: 50 mM Tris, pH D 7.5, 150 mM NaCl, 10 mM
CaCl2, 0.05% Brij-35 and 1% DMSO). Activated enzyme (final
concentration 0.56 nM for MMP-2, 1.3 nM for MMP-9, 1.0 nM
for MMP-14cd, 2.0 nM for MMP-1, 5 nM for ADAM-17 and
20 nM for ADAM-10) and inhibitor solutions were incubated in
the assay buffer for 3 h at 25C. ADAM-17 was incubated for
30 min at 37C and ADAM-10 for 1 h at 37C in a different
buffer at pH D 9 (25 mM Tris, 25 mM ZnCl2, 0.005% Brij-35).
After the addition of 200 mM solution of the fluorogenic sub-
strate Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2
(Bachem) for all the enzymes in DMSO (final concen-
tration 2 mM for all enzymes, 10 mM for ADAM10), the
hydrolysis was monitored every 15 sec for 20 min
recording the increase in fluorescence (λex D 325 nm,
λem D 400 nm) with a Molecular Devices SpectraMax
Gemini XPS plate reader. The assays were performed in
duplicate in a total volume of 200 mL per well in 96-
well microtitre plates (Corning black, NBS). Control
wells lack inhibitor. The MMP inhibition activity was
expressed in relative fluorescent units (RFU). Percent of
inhibition was calculated from control reactions without
the inhibitor. IC50 was determined using the formula:
vi/vo D 1/(1 C [I]/ IC50), where vi is the initial velocity
of substrate cleavage in the presence of the inhibitor at
concentration [I] and vo is the initial velocity in the
absence of the inhibitor. Results were analyzed using
SoftMax Pro software and GraFit software.
Small interfering RNA (siRNA) transfection. ON-TARGET plus
SMART pool for human ADAM10 or ADAM17 (100 nM, Dhar-
macon CarloErba, Milan, Italy) were used to knockdown the
expression of ADAM10 or ADAM17; siCONTROL non-targeting
(NT) siRNA pool (Dharmacon) was used as negative control. L428
(2.5£ 105) were transfected by electroporation with Microporator
MP-100 (Digital Bio) at the following electric conditions: Pulse
voltage: 1400, pulse width: 10, pulse number: 3. Accel delivery sys-
tem (Dharmacon) was used for KMH2 cell line, difficult to trans-
fect. Briefly, 4 £ 105cells were incubated with 1 mM Accell
SMARTpool ADAM10 or ADAM17 siRNA or Accell non-target-
ing siRNA pool in Accell siRNA delivery medium for 72 h. Protein
expression by western blot and immunofluorescence was analyzed
72 h after transfection. Soluble NKG2D-L were evaluated by ELISA
in conditioned media collected from silenced cells upon further
24 h of culture after transfection.
Western blot. LN cell suspensions, prepared as described,16or
HL cell lines were harvested and lysed with ice-cold RIPA
buffer containing protease and phosphatase inhibitors. Protein
quantification in cell lysates was done with the DC Protein
Assay Kit (Bio-Rad, Hercules, CA, USA). Equal amounts of
protein (20 mg/lane) were loaded on precast 8–16% gradient
gels (Thermo Fisher Scientific, Waltham, MA, USA) and then
electro-transferred to PVDF membranes (GE Healthcare, Little
Chalfont, UK). After blocking, membranes were probed over-
night at 4C with the rabbit polyclonal anti-ADAM17
(ab39163, Abcam, Cambridge, UK) or the anti-ADAM10 mAb
(MAB1427 anti-ectodomain, R&D System) diluted according
to the manufacturer’s instructions. After washing, membranes
were incubated for 1 h at room temperature with the relevant
horseradish peroxidase (HRP)-conjugated secondary antibod-
ies (Cell Signaling, EuroClone, Milan, Italy), and proteins were
detected by Immobilon Western Chemiluminescent HRP Sub-
strate (Millipore, Billerica, MA, USA). Anti-b-actin HRP-con-
jugated antibody (Cell Signaling) was used as a loading control.
Densitometric analysis was performed using the ImageJ com-
puter program (http://imagej.nih.gov/ij/download.html) and it
is reported as fold change relative to controls set to 1.
Some samples were deglycosylated with N-glycosidase F
(PNGase F, New England Biolabs) according to the manufac-
turer’s instructions. Briefly, 35 mg of HL cell lysates were
digested overnight with PNGase F before western immunoblot
with the specific anti-MICA/B antibody (BAMO1, Axxora
GmbH, Grafelfing Germany). HeLa cells, homozygotes for the
allelic variant MICA008, and MDA-MB-231 were used as
references.28
Immunofluorescence and cytofluorimetric analysis. Immuno-
fluorescence on HL cells or on HL LN suspensions was per-
formed with the anti-ADAM10 mAb (MAB1427) or the anti-
CD30 mAb or the Ig-NKG2D chimera (FcNKG2D), purchased
from R&D System, the anti-MIC-A mAb M2032B528 or the
anti-MIC-B mAb (clone 12, Sino Biologicals Inc., Beijing,
China) and the anti-ULPBs mAbs (anti-huULBP2 M311 and
anti-huULBP3 M551) kindly provided by Amgen (Seattle, WA,
M.T.A. no. 200309766-001) or the anti-ALCAM antibody
(MAB6561, R&D System). In some experiments, TGFb (recom-
binant human TGFb1, R&D) was added to either NK or gd T
cells at 10 ng/mL for 12 h, in the presence or absence of saturat-
ing amounts of the anti TGFb mAb (1 mg/mL, clone 1D11,
R&D), before staining with the anti-NKG2D mAb (MAB139,
R&D System). Some experiments were performed after cell
exposure to the ADAM10 inhibitors GIX, JG26, LT4, MN8, at
10mMor 5mMconcentration; in some samples 100mM sodium
orthovanadate (Na3VO4, Sigma Chemicals Co., St Louis, MO)
was added as pervanadate (obtained with 100 mM H2O2) for
40 min at 37C, to maximize the ADAMs enzymatic activity.25,26
This dose and time of treatment were not toxic for the HL cell
lines tested, as evaluated by JC1 staining (not shown). Samples
were stained with the indicated mAbs for 30 min at 4C, fol-
lowed by anti-isotype goat anti-mouse (GAM) or anti-rabbit
(GAR) antiserum conjugated with the appropriate fluoro-
chromes and analyzed by CyAn ADP flow cytometer (Beckman
Coulter, Inc.). Control aliquots were stained with isotype-
e1123367-8 M. R. ZOCCHI ET AL.
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matched irrelevant mAbs. Results are expressed as log of mean
fluorescence intensity (MFI) or percentage of positive cells, or as
the ratio between the MFI of each sample and the negative con-
trol, as indicated in the figure legend.
Cytotoxicity assay. Cytolytic activity of NK and gd T cells was
analyzed against L540, L428 or KMH2 cell lines at an E:T ratio
of 10:1, in V-bottomed microwells, in a 4-h 51Cr-release assay as
described.15,16 Some samples were set up after exposure of the
target cell lines to each ADAM10 inhibitor (GIX, JG26, LT4 or
MN8) at 10 mM concentration for 24 h. In some samples, the
effector cells were exposed to saturating amounts (5 mg/mL) of
the anti-NKG2D mAb at the onset of the cytotoxicity assay; an
unrelated mAb, matched for the isotype (BD PharMingen, BD
Italia, Milan, Italy), was used as control. Other experiments were
performed by adding to the effector cells TGFb (at 10 ng/mL for
12 h, in the presence or absence of saturating amounts of the
anti TGFb mAb (1 mg/mL), before starting the cytotoxicity
assay. One hundred microliters of SN were measured in a
gamma counter and the percentage of 51Cr-specific release was
calculated as described previously. The percentage of specific
release was calculated with the following formula: experimental
release (counts)-spontaneous release (counts)/maximum release
(counts)-spontaneous release (counts). Maximum and sponta-
neous release was calculated as described.
ELISA for sMIC-A/B, sULBP2/3, and sALCAM. Soluble (s)
MIC-A, sMIC-B, sULBP2, sULBP3 and sALCAMwere measured
in SN by ELISA as described.15,16 SN were collected from cell cul-
tures (HL cell lines), before or after 24 h exposure to the various
ADAM10 inhibitors (GIX, JG26, LT4, MN8, from 10 mM to
1 mM). In some samples, 100 mM sodium orthovanadate was
added as pervanadate for 40 min before collecting SN. The anti-
MIC-A mAbs AMO1 and BAMO3 were from Immatics Biotech-
nologies (Tubingen, Germany) and the anti-ULPBs mAbs (anti-
ULBP2 M311, IgG1; anti-ULBP3 M551, IgG1) were provided by
Amgen (Seattle, WA). The anti-ULBP2 and anti-ULBP3 detec-
tion mAbs (MAB1298, IgG2a; MAB15171, IgG2a) and the ELISA
detection kit for sMIC-B and sALCAM (DuoSet) were from R&D
System. Anti-mouse IgG2a HRP was from Southern Biotechnol-
ogy Associates (Birmingham, AL). Plates were developed with
2,2-azinobis (2-ethylbenzothiazoline-6-sulfonic acid) (Sigma)
and read at OD450nm. Results are expressed as ng/mL and
referred to a standard curve obtained with the MIC-A/B/Fc,
ULPB2/Fc or ULBP3/Fc chimeras (R&D System). sMIC-A and
sULBP3 content was measured by ELISA also in SN from LN cell
suspensions cultured overnight at 106/mL.
Statistical analysis. Data are presented as mean§ SD. Statisti-
cal analysis was performed using two-tailed student’s t test. The
cut-off value of significance is indicated in each legend to figure.
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